scholarly journals Placental extract ameliorates liver fibrosis in a methionine- and choline-deficient diet-induced mouse model of non-alcoholic steatohepatitis

2020 ◽  
Vol 41 (1) ◽  
pp. 1-12
Author(s):  
Akihiro YAMAUCHI ◽  
Takahiro TONE ◽  
Andreia de TOLEDO ◽  
Kyoko IGARASHI ◽  
Koji SUGIMOTO ◽  
...  
Author(s):  
Mayuko Ichimura-Shimizu ◽  
Yosuke Tsuchiyama ◽  
Yuki Morimoto ◽  
Minoru Matsumoto ◽  
Tomoko Kobayashi ◽  
...  

2015 ◽  
Vol 15 (1) ◽  
Author(s):  
Yuichi Nozaki ◽  
Koji Fujita ◽  
Koichiro Wada ◽  
Masato Yoneda ◽  
Takaomi Kessoku ◽  
...  

2008 ◽  
Vol 23 (12) ◽  
pp. 1909-1916 ◽  
Author(s):  
Haruko Sugino ◽  
Naoki Kumagai ◽  
Sakiko Watanabe ◽  
Kyoko Toda ◽  
Osamu Takeuchi ◽  
...  

2016 ◽  
Vol 23 (3) ◽  
pp. 132-141 ◽  
Author(s):  
Helena Cortez-Pinto ◽  
Paula Borralho ◽  
Jorge Machado ◽  
Maria T. Lopes ◽  
Inês V. Gato ◽  
...  

2020 ◽  
Author(s):  
Xin Xin ◽  
Bei-yu Cai ◽  
Cheng Chen ◽  
Hua-jie Tian ◽  
Xin Wang ◽  
...  

Abstract Aims To establish a mouse model of non-alcoholic steatohepatitis (NASH) within liver fibrosis using a high-fat and high-carbohydrate diet (HFHC) and to analyze potential pathogenesis using a transcriptome microarray. Methods Sixty mice were stratified by weight and randomly divided into HFHC model and control (Con) groups, with 30 mice in each group. Both HFHC and Con mice were euthanized at 0, 20 and 30 weeks. The following analyses were performed: biochemical analysis; histological assessment; Col-I, α-SMA and TGF-β1 protein and mRNA expression levels; and transcriptomic gene chip analysis. Results Compared with the Con group at each time point, the body weight and liver wet weight of the HFHC model group mice were significantly higher. At 30 weeks, ALT, AST, FBG and FINS levels or activities and TG and HYP contents in the HFHC model group were significantly elevated. Severe steatosis was present in the liver tissues from HFHC group mice. Substantial perisinusoidal fibrosis with a cage-like structure and bridging formations were observed in the liver. Col-I, α-SMA and TGF-β1 protein and mRNA expression levels in liver tissues from HFHC mice increased over time. Compared with the Con group, the HFHC group had 151 differentially expressed genes that were involved in 41 signaling pathways. Conclusions After 30 weeks of a HFHC diet, the mice exhibited substantial liver fibrosis, hepatic steatosis, ballooning degeneration and inflammation. The formation of an experimental NASH combined with liver fibrosis mouse model may be related to ECM-receptor interaction, Toll-like receptor signaling and other signaling pathways.


2021 ◽  
Author(s):  
Nikolaos Perakakis ◽  
Konstantinos Stefanakis ◽  
Michael Feigh ◽  
Sanne Skovgard Veidal ◽  
Christos S. Mantzoros

Author(s):  
Yu Jung Heo ◽  
Sung‐E Choi ◽  
Nami Lee ◽  
Ja Young Jeon ◽  
Seung Jin Han ◽  
...  

Cancers ◽  
2021 ◽  
Vol 13 (7) ◽  
pp. 1515
Author(s):  
Keiichiro Okuda ◽  
Atsushi Umemura ◽  
Shiori Umemura ◽  
Seita Kataoka ◽  
Hiroyoshi Taketani ◽  
...  

Non-alcoholic steatohepatitis (NASH) has become a serious public health problem associated with metabolic syndrome. The mechanisms by which NASH induces hepatocellular carcinoma (HCC) remain unknown. There are no approved drugs for treating NASH or preventing NASH-induced HCC. We used a genetic mouse model in which HCC was induced via high-fat diet feeding. This mouse model strongly resembles human NASH-induced HCC. The natural product honokiol (HNK) was tested for its preventative effects against NASH progression to HCC. Then, to clarify the mechanisms underlying HCC development, human HCC cells were treated with HNK. Human clinical specimens were also analyzed to explore this study’s clinical relevance. We found that epidermal growth factor receptor (EGFR) signaling was hyperactivated in the livers of mice with NASH and human HCC specimens. Inhibition of EGFR signaling by HNK drastically attenuated HCC development in the mouse model. Mechanistically, HNK accelerated the nuclear translocation of glucocorticoid receptor (GR) and promoted mitogen-inducible gene 6 (MIG6)/ERBB receptor feedback inhibitor 1 (ERRFI1) expression, leading to EGFR degradation and thereby resulting in robust tumor suppression. In human samples, EGFR-positive HCC tissues and their corresponding non-tumor tissues exhibited decreased ERRFI1 mRNA expression. Additionally, GR-positive non-tumor liver tissues displayed lower EGFR expression. Livers from patients with advanced NASH exhibited decreased ERRFI1 expression. EGFR degradation or inactivation represents a novel approach for NASH–HCC treatment and prevention, and the GR–MIG6 axis is a newly defined target that can be activated by HNK and related compounds.


Sign in / Sign up

Export Citation Format

Share Document